Australia's Medadvisor slips on bleak FY25 outlook

Adheris Health

01/04/2025 03:12

** Medadvisor MDR.AX slides 12.7% to A$0.096, lowest since March 21

** Medication solutions co expects FY25 loss before interest, taxes, depreciation and amortization to be in the A$2.6 mln ($1.6 mln)-A$5.5 mln range

** Co reported FY24 EBITDA at A$7 mln

** MDR expects FY25 revenue between A$93 mln and A$99 mln, lower than year-ago A$122 mln

** Stock on track for weakest session since March 21

** MDR sheds 51.1% YTD

($1 = A$1.6023)

 (Reporting by Adwitiya Srivastava in Bengaluru)

 ((Adwitiya.Srivastava@thomsonreuters.com))